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Abstract 
We hypothesized that lymph node involvement in minor salivary gland cancers is 
associated with clinical and pathological factors commonly available to the 
clinician after a typical initial workup. Our aim was to identify these factors using 
a dataset that allowed us to compile the largest series of minor salivary gland 
cancers in the published literature. Using this dataset we also aimed to 
characterize the distribution of histological types by primary site, identify the 
predictors of the use of external beam radiation therapy and neck dissection, and 
examine the effect of lymph node involvement on survival. Using the SEER 
database, we identified 2667 minor salivary gland cancers with known lymph 
node status from 1988 to 2004. Univariate and multivariate analyses were 
conducted to identify factors associated with the use of neck dissection, the use 
of external beam radiation therapy, and the presence of cervical lymph node 
metastases. Kaplan Meier survival curves were constructed to examine the effect 
of lymph node involvement on survival. 426 (16.0%) patients had neck nodal 
involvement. Factors associated with neck nodal involvement on univariate 
analysis included increasing age, male gender, increasing tumor size, high tumor 
grade, T3-T4 stage, adenocarcinoma or mucoepidermoid carcinomas, and 
pharyngeal site of primary malignancy. On multivariate analysis, four statistically 
significant factors were identified, which included male gender, T3-T4 stage, 
pharyngeal site of primary malignancy, and high-grade adenocarcinoma or high-
grade mucoepidermoid carcinomas. The proportions (and 95% confidence 
intervals) of patients with lymph node involvement for those with 0, 1, 2, 3 and 4 
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of these prognostic factors were 0.02 (0.01-0.03), 0.09 (0.07-0.11), 0.17 (0.14-
0.21), 0.41 (0.33-0.49), and 0.70 (0.54-0.85) respectively. Grade was a 
significant predictor of metastasis for adenocarcinoma and mucoepidermoid 
carcinoma but not for adenoid cystic carcinoma. Overall survival was significantly 
worse at 5, 10, and 15 years for patients with lymph node involvement on 
presentation. A prognostic index using the four clinicopathological factors listed 
above can effectively differentiate patients into risk groups of nodal metastasis. 
The precision of this index is subject to the limitations of SEER data and it should 
be validated in further clinical studies.  
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Introduction  
Minor salivary gland cancers represent a rare group of epithelial 
malignancies. The most common site is the hard palate, but tumors can also 
arise throughout the oral cavity, as well as the pharynx, larynx, nasal cavity and 
paranasal sinuses. Tumors of the minor salivary glands are two to three times 
more likely to be malignant than parotid and submandibular gland tumors.1-3 
Overall, 25% of salivary gland cancers arise in minor salivary glands. These 
glands account for approximately five percent of saliva production.  
Metastasis of most minor salivary gland neoplasms typically occurs by 
lymphatic spread via the cervical lymph nodes. Cervical lymph node involvement 
is associated with decreased survival in both major4-10 and minor salivary gland 
cancers.11, 12 Anderson and colleagues analyzed 95 patients diagnosed and 
treated at the University of Alabama at Birmingham over a 35-year period.11 In 
multivariate analysis, three factors were predictive of increased disease-free 
survival at four years. These were stage I or II cancer, negative surgical margins, 
and the absence of cervical lymph node metastasis. These results emphasize 
the need for early detection—in order to treat the patient before they reach 
advanced stage—and the desirability of treating of cervical lymph nodes when 
they are present.  
Clinically positive lymph nodes are removed by surgical neck dissection 
often accompanied by neck irradiation. Patients believed to be likely to harbor 
occult nodal metastasis are treated with an elective neck dissection and/or neck 
irradiation. Clear, evidence-based guidelines that demonstrate which patients will 
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present with lymph node metastasis are currently lacking in the literature, 
although it is known that certain histological types such as adenoid cystic and 
acinic cell carcinomas are associated with less risk of neck metastasis.5, 13  
The factors that influence the occurrence of lymph node metastasis in the 
much more common squamous cell carcinoma of the upper aerodigestive tract 
have been reported. Woolgar and colleagues investigated the relationship 
between cervical lymph node metastasis and certain clinical and pathologic 
factors in 45 patients with tongue or floor of mouth tumors who received neck 
dissection.14 They found no relationship between lymph node metastasis and 
gender, age, primary site, TNM stage, or T stage. There was a significant 
relationship with the tumor surface dimension and two measures of tumor 
thickness. This study was limited by a small sample size.  
Tumor size and grade of malignancy were shown to predict for the risk of 
nodal metastasis in univariate analysis by Rodriguez-Cuevas and colleagues.15 
This study included 150 salivary gland tumors, of which only 18 were located in 
the minor salivary glands. Major gland cancers involved the cervical lymph nodes 
in 25/132 (18.9%) of cases and minor gland cancers involved the cervical lymph 
nodes in 4/18 (22%) of cases. Undifferentiated and squamous cell carcinomas 
(major glands only) had the highest rate of clinical node metastasis: 10/32 (31%). 
An intermediate group consisted of papillary carcinomas, involving the lymph 
nodes in 2 of 12 cases (17%), adenoid cystic carcinoma, involving the lymph 
nodes in 5 of 28 cases (17%), and mucoepidermoid carcinomas, involving the 
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lymph nodes in 9 of 48 cases (18%). The incidence in acinic cell carcinomas was 
only 1 in 14 (7%).  
Terhaard and colleagues analyzed 565 malignant salivary gland tumors 
(157 in the minor salivary glands) from the Dutch Head and Neck Oncology 
Cooperative Group in 2004 for independent prognostic factors for locoregional 
control.13 Eighty-nine percent were treated with curative intent. In multivariate 
analysis, local control was associated with clinical T stage, bone invasion, site, 
resection margin, and treatment. Regional control was associated with N stage, 
facial nerve paralysis, and treatment. There was a 9.7 relative risk for local 
recurrence with surgery alone, compared with surgery plus postoperative 
radiotherapy and a 2.3 relative risk for regional recurrence. Surgery alone was 
completed in 20% of the patients and surgery combined with radiation therapy 
was completed in 68% of the patients. Despite an imbalance of other prognostic 
factors favoring the surgery only group, the combined group had much lower 
rates of locoregional recurrence.    
In a study looking only at 145 surgically treated parotid carcinomas, Regis 
de Brito Santos found, in multivariate analysis, histological type 
(adenocarcinoma, undifferentiated carcinoma, high grade mucoepidermoid 
carcinoma, squamous cell carcinoma, and salivary duct carcinoma) (p < 0.001), 
T3 or T4 stage (p = 0.03), and severe desmoplasia (p = 0.006) to be 
independently associated with lymph node metastasis.16 In an analysis of the 
SEER database, Bhattacharyya and Fried examined the predictors of lymph 
node metastasis also in parotid carcinomas drawing on 1268 cases from 1988 to 
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1998. They concluded that facial nerve involvement, tumor grade, and squamous 
cell carcinoma subtype were the most important factors contributing to lymph 
node metastasis.17  
The evidence above is the best available for the identification of clinical 
and pathological associated with lymph node metastasis in minor salivary gland 
cancers. Unfortunately, most of the studies deal mostly with major salivary gland 
cancers or squamous cell carcinomas of the upper aerodigestive tract.  
This study attempts to answer the question for minor salivary gland 
cancers using the National Cancer Institute’s Surveillance, Epidemiology and 
End Results (SEER) database. The SEER database is a collection of cancer 
registries that has historically included 14% of the U.S. population. As more 
registries have been added over the years, that percentage has grown to 
approximately 25%.  
 
Statement of Purpose, Specific Hypothesis, and Specific Aims of the 
Thesis 
We used the SEER database to compile the largest, population-based 
dataset of malignant minor salivary gland cancers yet reported. We describe 
demographic, clinical and pathological characteristics of these tumors including 
the distribution of histological type by the site of the primary malignancy. We 
hypothesized that some patient and tumor characteristics commonly known by a 
clinician faced with the decision to treat the cervical lymph nodes may help define 
risk classes for lymph node involvement. We examined these associations with 
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cervical lymph node metastasis both by univariate analysis and while controlling 
for other variables. A simple prognostic index was derived to predict the 
presence of lymph node metastasis using the four most important 
clinicopathological factors. We also analyze the clinicopathological 
characteristics associated with treatment with external beam radiation therapy 
and surgical neck dissection. Finally, we examined the survival of patients with 
lymph node metastasis versus those without.  
 
Methods 
All procedures and analysis outlined in the following section were 
conduced by Shane Lloyd, the thesis candidate. Exemption from IRB review was 
obtained for this study as the study does not involve human subjects and the 
data is on a freely available public database.  
We queried the National Cancer Institute’s SEER registries database to 
select minor salivary gland malignancies from 1988 to 2004. Minor salivary gland 
malignancies were defined by primary site and histological criteria as follows. 
Primary site criteria included cancers of the oral cavity, pharynx, nasal cavity, 
and larynx. The oral cavity included the lips (C00.0-C00.9), tongue (C020-C023, 
C028-C029), gingiva (C030-C039, C062), floor of mouth (C040-049), hard palate 
(C050), and buccal mucosa (C060-C061). The pharynx included the base of 
tongue (C019), tonsils (C024), soft palate (C051-C052), and all other pharyngeal 
sites (C090-C139). The larynx included all laryngeal sites (C320-C329). Finally, 
the nasal cavity was grouped with the nasal cavity itself (C300), the middle ear 
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(C301) and paranasal sinuses (C310-C319). Pathologic criteria included the 
salivary gland malignancies described in the World Health Organization 
International Histological Classification of Tumors.18 Seventy-four cases were 
excluded from analysis because they were not the patient’s first known head and 
neck malignancy. Excluding these cases ensures that the source of nodal 
metastasis is the primary cancer in question. To present a complete population-
based survey of the distribution of histological types in the various primary sites, 
we included patients whether or not their lymph node status was known. In all 
subsequent analyses, 1259 cases with unknown or unrecorded lymph node 
status were excluded leaving a final dataset of 2667 patients. Complete patient 
characteristics are presented for this final set of patients.  
 All staging information including lymph node involvement represents the 
information available on the initial workup or upon the completion of the first 
primary directed surgery or surgeries. Disease progression known to have 
occurred after the original date of diagnosis is not included. As the SEER 
program does not record T stage before 2004, we used information recorded in 
the SEER program on tumor size and extension19 to assign T stage as defined 
by the AJCC Cancer Staging Manual, 6th edition, 2002. This method resulted in T 
stage assignment that was identical to that found in SEER’s derived AJCC T 
stage variable that is available only for 2004.   
Clinical and pathological factors potentially associated with neck lymph 
node metastasis were identified and included patient gender, age, race 
(Caucasian, African American, or other), site of primary malignancy, tumor grade, 
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tumor size, T stage, and year of diagnosis. Grade information was grouped into 
low-grade (well differentiated to moderately differentiated) and high-grade (poorly 
differentiated or undifferentiated/anaplastic) categories. All variables were 
examined individually using the Pearson double-sided chi square test for their 
effect on lymph node involvement. Statistically significant factors were then 
included in a multivariate logistic regression model. Because more extensive 
nodal sampling or neck dissection may lead to a higher probability of finding 
positive lymph nodes, we included an independent variable for the number of 
nodes examined. Interactions between explanatory variables were also 
considered. We searched for interaction terms by forcing entry of all variables 
individually and allowing entry of interaction terms in forward stepwise fashion 
with a likelihood ratio significance cutoff of 0.05. Finally, the four most significant 
factors were combined into a categorical variable of 16 groups representing all 
possible permutations of the presence or absence of these four factors. This 
categorical variable was then re-entered in the logistic regression with the same 
covariate controls. Groups with similar odds ratios were combined in order to 
construct an index predictive of the presence or absence of lymph node 
involvement in minor salivary gland cancers. This index was then validated using 
10-fold cross-validation.  
Generally, we omitted cases from our logistic regressions if input variables 
were missing. This reduces the power and has the potential to introduce bias into 
our analysis. As a safeguard against this, we used maximum likelihood 
estimation to impute the missing data in our regression of clinicopathological 
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factors on lymph node involvement. This is a statistical way of making a best 
guess at missing variables—such as stage or tumor size—based on the known 
characteristics of each case with a missing variable. We imputed the data five 
times and the estimated values were combined to arrive at beta and standard 
deviation estimates that take advantage of all the data. This was done to affirm 
the independent statistical significance of each of the variables included in the 
index. Only known information and no imputed information was used in 
constructing the index or in other analyses in this study.  
The clinicopathological variables listed above were also examined for their 
association with neck dissection and external beam radiation by logistic 
regression. A neck dissection was defined as any case with four or more lymph 
nodes examined by a pathologist. The Hosmer-Lemeshow goodness-of-fit 
statistic was used to evaluate regression outputs. Patients with distant 
metastasis were excluded from multivariate analyses of lymph node metastasis 
and survival analysis. A receiver operator curve was generated for the prognostic 
index of lymph node involvement in minor salivary gland cancer.  
Finally, we generated Kaplan-Meier survival curves for patients with and 
without lymph node metastasis respectively.  
Univariate analysis, multivariate logistic regression, Hosmer-Lemeshow 
tests, receiver operator curves, and Kaplan-Meier survival curves were computed 
using SPSS version 16 (SPSS Inc., Chicago, IL). Cross-validation was computed 
using the R programming language with the Zelig package.20 Multiple imputation 
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of missing data was conducted using the R programming language with the Zelig 
and AmeliaView21 packages. 
 
 
 
 
Results 
Table 1: Location of 4616 Cases of Minor Salivary Gland Cancer by 
Histological Type. 
Percentages in parentheses represent the percentage of cancers in the site that 
are the histological type in question. Percentages in the bottom row represent the 
percentage of the total found in that site.  
 
The distribution of histological type by primary tumor site is listed in Table 
1. Patient and tumor characteristics and the results of univariate analysis of the 
effects of each clinical or pathologic factor individually on lymph node metastasis 
are shown in Table 2. Overall, lymph node metastasis was found in 426 (16.0%) 
of cases. In patients who underwent surgery and were staged by pathology, 
54.2% had lymph node metastasis. In patients who were staged clinically, 8.8% 
had lymph node metastasis.  
 
 
Oral Cavity (%) 
Pharynx and 
Tonsils (%) 
Nasal Cavity, 
Sinuses, 
Middle Ear (%) Larynx (%) Total (%) 
Adenocarcinoma 654  (29.9) 350 (38.9) 280 (41.4) 100  (62.1) 1384 (35.3)
Mucoepidermoid Carcinoma 991 (45.3) 262 (29.1) 62 (9.2) 18 (11.2) 1333 (34.0) 
Adenoid Cystic Carcinoma 436 (19.9) 249 (27.7) 307 (45.4) 30 (18.6) 1022 (26.0) 
Acinic Cell Carcinoma 60  (2.7) 14 (1.6) 7 (1.0) 0 - 81 (2.1)
Miscellaneous Carcinoma 48 (2.2) 25 (2.8) 20 (3.0) 13  (8.1) 106 (2.7) 
Total (% of Total in Site) 2189 (55.8) 900 (22.9) 676 (17.2) 161 (4.1) 3926  
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Table 2. Patient Characteristics and Clinical and Pathologic Factors and 
Their Effect on Nodal Involvement in Univariate Analysis. 
Baseline Characteristic  Total No. (%) 
Incident Nodal 
Involvement (%) P-Value* 
Gender     < 0.001 
Female 1423 (53.4) 11.4  
Male  1244 (46.4) 21.2  
Race      0.052 
Caucasian 2101 (79.6) 15.6  
African American 324 (12.3) 20.4  
Other 216 (8.2) 13.4  
Histological Type    < 0.001 
Adenoid Cystic Carcinoma 695 (26.1) 10.2  
Acinic Cell Carcinoma 41 (1.5) 2.4  
Mucoepidermoid Carcinoma 929 (34.8) 15.8  
Adenocarcinoma 929 (34.8) 21.3  
Miscellaneous Carcinoma 73 (2.7) 12.3  
Grade    < 0.001 
Low-Grade  1299 (73.8) 8.5  
High-Grade 461 (26.2) 39.9  
Primary Site    < 0.001 
Mouth 1493 (56.0) 9.7  
Pharynx Including Tonsil  667 (25.0) 32.5  
Nasal Cavity, Sinuses, Middle Ear  397 (14.9) 6.8  
Larynx    110 (4.1) 33.6  
T Stage    <  0.001 
T1 945 (44.1) 6.1  
T2  401 (18.7) 20.4  
T3 190 (8.9) 20.5  
T4 514 (24.0) 21.6  
Neck Dissection (> 3 Nodes Examined)   < 0.001 
Yes 391 (14.8) 54.2  
No 2257 (85.2) 8.8  
EBRT   < 0.001 
Yes 1125 (43.4) 28.5  
No 1466 (56.6) 6.2  
 
 
Total No. 
LNs 
Involved 
Mean 
(SE) 
No LNs 
Involved 
Mean 
(SE) 
 
Age  2667 57.7 (0.4) 60.9 (0.7) < 0.001 
Year of Diagnosis  2667 1999 1998 0.005 
Tumor Size (mm)  1828 24.6 (0.7) 32.9 (1.1) < 0.001 
Number of Nodes Examined  2667 1.4 (0.1) 15.7 (1.1) < 0.001 
*Pearson Chi square test double-sided p-value. SE: Standard Error. 
The T stage is unknown for 92 patients who had distant metastasis because 
distant metastasis overrides tumor extension data in SEER coding. LN = Lymph 
Node.  
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To arrive at a model that illustrates the relative importance of factors 
commonly available to physicians considering neck dissection and/or neck 
irradiation, we included clinical and pathological factors found to be significant on 
univariate analysis in a multivariate logistic regression on lymph node 
involvement (Table 3). An interaction was found between grade and histology 
such that adenocarcinomas and mucoepidermoid carcinomas were more likely to 
present with lymph node metastasis when they were high-grade. However, grade 
had no effect on nodal involvement for other histological types or sub-types. We 
therefore considered low- and high-grade malignancies separately for 
adenocarcinomas and mucoepidermoid carcinomas but not for the other 
histological types.  
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Table 3: Multivariate Logistic Regression of Clinicopathological Factors on 
Regional Nodal Metastasis. 
Variable (Comparison Group for Categorical 
variables) 
Odds Ratio (95% 
Confidence Interval) P-Value 
Histological Type and Grade  
(v. Adenoid Cystic Carcinoma) 
  
< 0.001 *** 
     Acinic Cell Carcinoma 0†    
     Mucoepidermoid Carcinoma, Low-Grade 1.06  (0.56-2.02) 0.858  
     Mucoepidermoid Carcinoma, High-Grade 4.04  (2.09-7.80) < 0.001 *** 
     Adenocarcinoma, Low-Grade 1.91  (1.04-3.51) 0.037 * 
     Adenocarcinoma, High-Grade 6.72  (3.48-13.00) < 0.001 *** 
     Miscellaneous 1.73  (0.40-7.44) 0.461  
Primary Site (v. Mouth)    < 0.001 *** 
     Pharynx Including Tonsil 3.54  (2.27-5.54) < 0.001 *** 
     Nasal Cavity, Sinuses, and Middle Ear 0.71  (0.30-1.69) 0.443  
     Larynx   1.55  (0.55-4.40) 0.407  
T Stage (v. T1)  0.030 * 
T2 1.68 (0.95-2.97) 0.074  
T3 2.57 (1.19-5.55) 0.017 * 
T4 2.25 (1.26-4.04) 0.006 ** 
Male Sex (v. Female) 2.16  (1.42-3.30) < 0.001 *** 
Tumor Size (mm) 1.00  (0.99-1.01) 0.947  
Age 1.01  (1.00-1.02) 0.161  
Race (v. Caucasian)   0.268  
     African American 1.61  (0.91-2.87) 0.105  
     Other 1.08  (0.49-2.36) 0.852  
Controls     
Year of Diagnosis 0.99  (0.95-1.04) 0.698  
Number of Nodes Examined (v. None)   < 0.001 *** 
1-3 5.43  (2.69-10.97) < 0.001 *** 
> 3 24.01  (14.99-38.46) < 0.001 *** 
1533 patients are included in this analysis. The p-value is listed for the odds ratio 
of each variable and for the Wald statistic for inclusion of complete categorical 
variable groups. Cases with distant metastasis are excluded from this analysis 
because T stage was not recorded/unknown when there was distant metastasis. 
The Hosmer-Lemeshow test for this regression had a p-value of 0.023. The 
NagelKerke R Square is 0.526. ***p < 0.001. **0.001 < p <= 0.010. *0.010 < p <= 
0.050. †The number of lymph node positive cases is too small for analysis.  
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Controlling for all factors listed, male gender, pharyngeal primary site, T3 
or T4 stage, and high-grade adenocarcinoma or high-grade mucoepidermoid 
carcinoma are statistically significant predictors of regional nodal metastasis. 
When these four variables were combined into a single categorical variable of 16 
groups representing all possible permutations of their presence or absence, they 
resulted in the odds ratios listed in Table 4. Groups based loosely on these odds 
ratios were delineated which corresponded with the number, zero through four, of 
the four variables present.  Because of this, a predictive index for lymph node 
involvement is proposed based on the number present of the following four 
factors: male gender, pharyngeal primary site, T3 or T4 stage, and high-grade 
adenocarcinoma or mucoepidermoid carcinoma (Table 5). The area under the 
receiver operator curve (95% CI) using this index was = 0.757 (0.724-0.790). If 
one uses a positive test cutoff of one factor present, the sensitivity and specificity 
were 95.4% and 28.4%. Using two factors as the positive test cutoff results in a 
sensitivity and specificity of 66.9% and 72.2%, using three factors results in a 
sensitivity and specificity of 35.6% and 94.0%, and using all four factors results in 
a sensitivity and specificity of 10.0% and 99.4%. When the predictive capability of 
the logistic regression model which uses the number of factors present examined 
using 10-fold cross validation, the average squared prediction error was 0.0923 
indicating accurate prediction of the presence or absence of lymph node 
involvement when dividing the data into training and validating sets differently 10 
times.  
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Table 4: Odds Ratios of Combinations of the Presence or Absence of Four 
Factors. 
Odds ratios compare groups to the group with no factors present. ADC: 
Adenocarcinoma. MEC: Mucoepidermoid carcinoma. N = 1805 
 
 As mentioned above, we also used maximum likelihood estimation to 
accomplish multiple imputation of missing data to increase the power of our 
regression and eliminate potential sources of bias. The results of this process are 
found in Table 6. The same four factors included in the index are again shown to 
be significant although to slightly different degrees.   
Variable  
Lymph Node Positive Logistic Regression 
Cases 
Lymph 
Node 
Positive 
Proportion (95% 
Confidence 
Interval) 
Odds Ratio (95% 
Confidence Interval) P-Value 
All Factors Absent 9/457 0.02 (0.01-0.03)    
One Factor Present     
Male 17/326 0.05 (0.03-0.08) 2.18  (0.92-5.19) 0.078 
T3-4 22/219 0.10 (0.06-0.14) 3.77  (1.62-8.77) 0.002 
Pharynx 18/163 0.11 (0.06-0.16) 3.99  (1.65-9.62) 0.001 
High-Grade ADC or MEC 8/45 0.18 (0.07-0.30) 5.562  (1.79-17.33) 0.003 
Two Factors Present        
Male and T3-4 19/191 0.10 (0.06-0.14) 3.69  (1.55-8.81) 0.003 
Male and Pharynx 15/99 0.15 (0.08-0.22) 6.08  (2.38-15.55) < 0.001 
T3-4 and High-Grade ADC or MEC 6/31 0.19 (0.05-0.33) 6.64  (1.88-23.52) < 0.001 
T3-4 and Pharynx 7/35 0.20 (0.07-0.33) 6.94  (2.12-22.76) 0.001 
Male and High-Grade ADC or MEC 15/41 0.37 (0.22-0.51) 11.70  (4.14-33.07) < 0.001 
Pharynx and High-Grade ADC or MEC 10/20 0.50 (0.28-0.72) 16.29  (4.58-57.92) < 0.001 
Three Factors Present      
All but Pharynx 20/60 0.33 (0.21-0.45) 17.25  (6.65-44.75) < 0.001 
All but High-Grade ADC or MEC 13/40 0.33 (0.18-0.47) 21.03  (7.39-59.87) < 0.001 
All but Male  8/15 0.53 (0.28-0.79) 29.64  (7.09-123.98) < 0.001 
All but T3-4 19/30 0.63 (0.46-0.81) 49.65  (16.04-153.75) < 0.001 
All Four Factors Present     
All 23/33 0.70 (0.54-0.85) 79.16  (26.07-240.35) < 0.001  
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Table 5: Predictive Index of Lymph Node Involvement in Minor Salivary 
Gland Cancer. 
Variable  
Predictive Index Logistic Regression 
Cases 
Lymph 
Node 
Positive 
Proportion (95% 
Confidence 
Interval) 
Odds Ratio (95% 
Confidence Interval) P-Value 
Number of Factors (v. 0)        
0 9/457 0.02 (0.01-0.03)   < 0.001
1 65/753 0.9 (0.07-0.11) 3.29  (1.56-6.93) 0.002 
2 72/417 0.17 (0.14-0.21) 6.15 (2.91-13.04) < 0.001 
3 60/145 0.41 (0.33-0.49) 24.47  (10.96-54.61) < 0.001 
4 23/33 0.70 (0.54-0.85) 81.64 (26.71-249.54) < 0.001 
The logistic regression includes the covariate controls listed in Table 3. Hosmer-
Lemeshow statistic p-value is 0.133 indicating no difference between predicted 
and observed values. NagelKerke R square is 0.464. 
 
Multivariate logistic regressions were conducted to determine the factors 
associated with a patient’s receiving a neck dissection or EBRT. Patients with 
T2-T4 stage tumors were more likely to receive neck dissection than patients 
with T1 stage tumors. Patients more likely to receive a neck dissection were 
those with T2-T4 tumors, those with high-grade tumors, and those living in 
Connecticut. Patients with tumors occurring in the sinuses/nasal cavity/middle 
ear were less likely to receive neck dissection.  
Forty-six percent of patients received EBRT. Patients who received 
surgical neck dissection were also more likely to receive EBRT. Patients with 
adenoid cystic carcinoma were more likely to receive EBRT, as were older 
patients, those with T2-T4 stage, and those with high-grade tumors. Patients less 
likely to receive EBRT were those with tumors occurring in the oral cavity, those 
living in Los Angeles, and those diagnosed in the later years of the study. 
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Table 6: Multivariate Logistic Regression of Clinicopathological Factors on 
Regional Nodal Metastasis Using Imputed Data 
Variable (Comparison Group for Categorical 
variables) 
Odds Ratio (95% 
Confidence Interval) P-Value 
Histological Type and Grade  
(v. Adenoid Cystic Carcinoma) 
  
  
     Acinic Cell Carcinoma 0.60 (0.13-2.65) 0.51  
     Mucoepidermoid Carcinoma, Low-Grade 1.14 (0.82-1.59) 0.43  
     Mucoepidermoid Carcinoma, High-Grade 3.79 (2.72-5.28) < 0.001 *** 
     Adenocarcinoma, Low-Grade 1.21 (0.90-1.63) 0.21  
     Adenocarcinoma, High-Grade 4.10 (2.90-5.80) < 0.001 *** 
     Miscellaneous 1.15 (0.56-2.38) 0.70  
Primary Site (v. Mouth)      
     Pharynx Including Tonsil 3.05 (2.09-4.44) < 0.001 *** 
     Nasal Cavity, Sinuses, and Middle Ear 0.54 (0.39-0.76) < 0.001 *** 
     Larynx   1.84 (1.18-2.88) 0.01  
T4 Stage (v. T1-3) 1.87 (1.42-2.47) < 0.001 *** 
Male Sex (v. Female) 1.57 (1.28-1.95) < 0.001 *** 
Tumor Size (mm) 1.00  (1.00-1.00) 0.65  
Age 1.01  (1.00-1.01) 0.04 * 
Race (v. Caucasian)     
     African American 1.09 (0.81-1.46) 0.58  
     Other 0.98 (0.60-1.60) 0.92  
Controls     
Year of Diagnosis 0.99 (0.97-1.00) 0.15  
 
 Finally, survival curves were generated to depict the relative survival of 
patients with nodal metastasis versus those with no nodal metastasis (Figure 1). 
For patients who were lymph node negative on presentation, the 5-, 10-, and 15-
year Kaplan-Meier overall survival (Standard Error in parentheses) was 78.4 
(1.2), 61.3 (1.9), and 52.5 (2.4). For patients with lymph node involvement on 
presentation, the 5-, 10-, and 15-year Kaplan-Meier overall survival was 42.4 
(3.4), 25.7 (3.9), and 11.9 (5.0).  
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Figure 1: Survival By Lymph Node Status. 
 
 
The upper curve represents patients who were lymph node negative on 
presentation and the lower curve represents patients with lymph node 
involvement on presentation.  
 
 
Discussion 
 
Location of Minor Salivary Gland Malignancies and Distribution of 
Histological Types 
We present the largest population-based dataset on the distribution of 
histological type by primary site to date. The oral cavity was the most common 
site and the hard palate the most common sub-site. We report a larger proportion 
of mucoepidermoid carcinoma than adenoid cystic carcinoma overall as opposed 
to others’ findings that adenoid cystic carcinoma is the most common type.1, 3, 22 
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Adenoid cystic carcinoma was the most prevalent sinonasal minor salivary gland 
malignancy, mucoepidermoid was most prevalent in the oral cavity, and 
adenocarcinomas were common in the pharynx and larynx.  
The frequency at which certain histological types of minor salivary gland 
cancers were diagnosed has changed over time. For example, polymorphous 
low-grade adenocarcinomas were diagnosed only in the later years of the study 
period from 2000-2004 and a total of 141 of these tumors were diagnosed during 
that time. The separation of adenocarcinomas into low-and high-grade groups 
should neutralize the absence of this diagnosis in the earlier years for the 
purposes of our analysis. Mixed pleomorphic carcinoma is a diagnosis that has 
come into usage only in the later years of the study.1 Only 11 cases were found 
of this type.  
 
 Grade as a Predictive Factor of Lymph Node Metastasis  
 Grade was predictive of nodal metastasis for adenocarcinoma and 
mucoepidermoid carcinoma but not for other histological types and sub-types. 
There was no statistically significant difference in the rate of lymph node 
metastasis between low and high-grade adenoid cystic carcinoma (ACC). Spiro 
and colleagues have similarly found that dividing ACC by grade was unhelpful for 
determining prognostic information for these tumors.3, 23 However, grade has 
been found by some authors to be helpful in predicting survival in ACC.24, 25 It is 
important to note that lymph node metastasis is generally considered less 
important than local and distant control in ACC, and distant metastases occurs 
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commonly even without neck nodal involvement in adenoid cystic carcinoma.24-27 
All but one acinic cell carcinomas in this study were low-grade. Similarly, all 
myoepithelial carcinomas were low-grade as were many adenocarcinoma sub-
types. Other histological types for which grade was not a statistically significant 
predictor of metastasis included mixed malignant tumor and pleomorphic 
carcinoma. The sample size may be insufficient to detect an interaction between 
grade and some histological sub-types including oxyphilic adenocarcinoma, 
ductal carcinoma, and carcinosarcoma. 
 
Race as a Potential Predictive Factor of Lymph Node Metastasis 
Our results suggest that African American patients may be more likely to 
present with nodal metastasis on univariate analysis. However, this was a trend 
that did not achieve statistical significance. Also, this trend dissipated when 
controlling for other factors on multivariate analysis. The factors controlled for 
include markers of disease severity like T stage and grade. This suggests that 
African American patients may be presenting with more advanced disease. 
African American patients have been shown to have a higher incidence and 
mortality regarding cancers of the oral cavity, pharynx and larynx than their white 
counterparts.28, 29 In one study of oral and squamous cell carcinomas, African 
American patients had decreased survival while controlling for stage and 
treatment.30 Differences in mortality and survival across racial groups are also 
more pronounced in men than in women.28    
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A Prognostic Index for Predicting Lymph Node Metastasis in Minor Salivary 
Gland Cancer 
While our reported rate of lymph node involvement of 16.0% is 
approximately commensurate with other published studies, a large, in depth case 
series may characterize the actual rate more accurately than SEER data. 
However, because minor salivary gland cancers are relatively rare, a case series 
this large may not be forthcoming in the immediate future. 
Occult nodal metastasis for major salivary malignancies is between 12 
and 20 percent.31-33 In a study of adenoid cystic carcinomas of the major and 
minor salivary glands, Spiro and colleagues reported a rate of lymph node 
involvement of 7.4% on initial presentation with an additional 7.0% developing 
positive lymph nodes subsequently.34 Occult nodal metastasis in high-grade 
adenocarcinoma was 40% in a small study by Sheahan and colleagues.35 They 
found occult disease in two out of five necks dissected electively.  High tumor 
grade was also correlated with occult metastasis in a study by Rodriguez-Cuevas 
and colleagues.15 In 36 elective neck dissections for major salivary gland 
cancers, 50% of high-grade tumors had occult metastasis while no low-grade 
tumors had occult metastasis. Because of limitations inherent to SEER data, it is 
not possible to determine which node positive patients had clinically occult nodal 
metastasis discovered in the operating room. However, our results have 
implications for these patients. Because the data represent a wide range of 
disease progression on presentation, patients who presented late with clinical 
nodal metastasis but who would have been clinically metastasis free had they 
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presented earlier are included. Three of the four factors found to be predictive of 
nodal metastasis in our analysis are characteristics that do not change over the 
progression of the malignancy such as histological type, primary site and gender. 
Therefore, it is reasonable to think that clinically N0 patients presenting with 
these factors are likely to go on and develop lymph node metastasis or already 
have occult metastasis at presentation. Our results should be validated in a set of 
patients with clinically N0 disease who also undergo neck dissection for 
pathological staging. 
  
 Recommendations For Using The Index 
While we do not assert that the percentages presented in the prognostic 
index are directly predictive of occult nodal metastasis, we do recommend 
consideration of the four factors listed when considering elective lymph node 
treatment. We would advocate that patients with three or four of the four factors 
should receive elective neck treatment.  Patients with two of the factors should 
also be strongly considered for elective neck treatment with neck dissection, 
adjuvant radiation therapy, or both. It is also worth cautioning that even patients 
with only one of the factors in the index may be appropriate candidates for 
elective therapy, especially if the one factor is high-grade adenocarcinoma or 
mucoepidermoid carcinoma. Because SEER data fails to capture neck relapses 
in patients who were N0 for the first 4 months after diagnosis, figures hovering 
around the cutoff range for elective treatment in the patients with one or two 
factors may actually be appropriate candidates. On the other hand, if 
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pretreatment staging with high resolution CT and ultrasound has failed to reveal 
regional lymphadenopathy, and the clinician feels the risk of occult metastasis is 
low, the model may also be used to identify patients who should have close 
follow up for regional progression. As with any prognostic tool, this index will not 
find complete applicability for each patient.  
Elective neck dissection or radiation therapy treatment of the neck even in 
high-risk patients may not convey local regional control or survival benefit. 
However, Tran and colleagues reported that post-operative radiation therapy 
improved local control in an analysis of 62 patients with minor salivary gland 
cancer arising in the oral cavity.36 In a separate report, they found better 
locoregional control with postoperative radiation therapy in 25 patients with minor 
salivary gland cancers of the paranasal sinuses or nasal cavity.37 In a series of 
256 minor salivary gland tumors in China, Chou and colleages showed that 
patients with positive cervical metastasis found during neck dissection had higher 
survival than those with no neck dissection.38 The methods employed were not 
robust enough to establish the superiority of elective dissection in N0 patients 
however.  
It is interesting to note that increasing size of the primary tumor was 
correlated with a patient receiving a neck dissection while it was not predictive of 
nodal metastasis while controlling for other factors. In some sites such as the 
sinuses and nasal cavity, tumors can attain large sizes before they present 
clinically. In the case of the sinuses or nasal cavity, lymphatic involvement is less 
likely. While T stage was found to be a significant factor predicting nodal 
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metastasis, it is surprising that it did not eclipse other factors in the index as 
might be expected.  
 
Dealing With Missing Data 
 The SEER program has a standard rate of case ascertainment of 98%.39 
However, staging and tumor grade information is often incomplete. Of 3926 
patients identified with minor salivary gland tumors, lymph node metastasis was 
only recorded for 2667. Furthermore, stage and grade information was not 
recorded for many patients such that the dataset of patients with no missing data 
pertinent to lymph node metastasis was only 1533. If these cases are not missing 
at random, then our regression has the potential to be biased. Statistical analysis 
indeed revealed some differences between the set of cases with fully recorded 
grade and stage information versus the set of cases excluded because of 
missing data. Cases with missing information tended to be in the earlier years of 
the dataset, come from certain geographic registries, be of Caucasian race, have 
high tumor grade, and have tumors in sites other than the mouth. Not 
significantly different between the two sets were T stage, tumor size, gender, 
age, and the use of external beam radiation therapy.  
In general, we excluded cases with missing data from multivariate logistic 
regression analysis. As a safeguard against the reduction in power and the 
potential introduction of bias into our analysis, we used maximum likelihood 
estimation to impute the missing data into our regression of clinicopathological 
factors on lymph node involvement. This helped affirm the independent statistical 
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significance of each of the variables included in the index. All four of these 
variables were independently associated with lymph node metastasis to a p-
value of less than 0.001, although their respective odds ratios differed from our 
main analysis. Older age was also found to be marginally significantly associated 
with lymph node metastasis in this analysis. Again, this imputation was used only 
as an exercise in testing the importance of missing variables in our construction 
of the prognostic index. As indicated in the methods section, multiple imputation 
was not used in constructing the index.  
 
 General Limitations of SEER Data 
Besides occasional missing data regarding grade and stage, SEER has 
some other important limitations that should be mentioned. One that is often cited 
is the lack of margin status. This is a more important consideration in studies that 
analyze the effects of various treatments on survival. For example, a study that 
examines the effect of adjuvant radiation therapy on survival for head and neck 
cancer must deal with the fact that patients with positive margins after surgery 
are more likely to receive adjuvant radiation therapy but also have a poorer 
prognosis. Other factors can be controlled for and one can exclude cases based 
on the extent of surgery but marginal status will remain a confounding variable.  
Another deficiency in SEER data is the lack of detail regarding the type, 
dose, energy, and techniques of radiation used. This is a problem for the present 
study only in our analysis of the clinicopathological characteristics associated 
with the used of external beam radiation therapy. Many of the patients were likely 
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treated only palliatively with lower doses and less extensive fields. Thus, they 
were not in essence “selected” for treatment in the sense that we imply.  
 
Choosing Target Volumes for Elective Treatment of the Neck: Skip 
Metastasis 
 Beyond knowing that certain minor salivary gland cancers metastasize to 
the neck, and that these patients might require elective treatment, the clinician 
needs a basis for selecting a target volume in the neck. This section and the next 
will present some current trends on treating two patterns of lymph node 
metastasis: skip metastasis and contralateral metastasis to the neck.   
A consensus on neck target selection guidelines for squamous cell 
carcinomas of the head and neck was reached at the 43rd annual meeting of the 
American Society of Therapeutic Radiology and Oncology in San Francisco, 
November 2001. This consensus was reported by Eisbruch and colleagues in 
2002 and applies only to patients with nodal stages N0 or N1.40 The guidelines 
state that clinical involvement of levels II or III always calls for treatment of levels 
Ib and IV ipsilaterally. Level V is always treated with ipsilateral involvement of 
levels II-IV. Lateral T1-T2 floor of mouth tumors require treatment of ipsilateral 
levels I-III and contralateral I-II. Ipsilateral level IV and contalateral level III are 
added for tumors of higher T stage. Tongue tumors of tumor stage T1-T2 require 
treatment of ipsilateral levels I-IV. More advanced T stages or tumors of the 
anterior tongue require the same levels contralaterally. Finally, buccal mucosa 
and retromolar trigone tumors require treatment of levels I-III ipsilaterally. 
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Furthermore, it was suggested that extracapsular extension of any lymph node 
calls for treatment of that neck level at a higher dose. For lateralized tumors of 
any head and neck site, contralateral neck treatment should be added when the 
N stage is greater than N1.  
For neck stages N2 and greater, treatment of ipsilateral levels I-V has 
been advocated in a consensus opinion published in 2006 by Gregoire and 
others.41 They recommend that the retrostyloid space be included in this volume 
if level II is involved, and that the supra-clavicular fossa be included if levels IV or 
Vb are involved. These authors also repeat the recommendations of a consensus 
opinion published in 2003 for the N0 or N1 patient.42 Specifically, they state that 
in the N0 or N1 patient, when a positive lymph node abuts a muscle, or shows 
radiological evidence of muscular infiltration, that the muscle should be included 
in the CTV, at least within the level at which the invasion occurs and with 1 cm 
margins. Also, they recommend that when an involved lymph node borders on 
two adjacent levels, that both levels should be treated. Finally, for the post-
operative patient, the abovementioned 2006 consensus recommendation was to 
include the entire operative bed, especially in the case of extracapsular 
extension. Then, for the post-operative patient, they repeat the recommendations 
of including the retrostyloid space in case of level II involvement and the 
supraclavicular fossa in case of level IV or Vb involvement, the inclusion of 
invaded muscles, and the inclusion of adjacent levels when a pathologically 
positive node borders on an undissected level.    
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Deciding Target Volumes for Elective Treatment of the Neck: Contralateral 
Lymph Node Involvement 
Contralateral lymph node involvement (CLNI) is not common but presents 
a challenge for the clinician who must decide whether to treat the contralateral 
neck. Most published studies on CNLI report on squamous cell carcinomas 
uniquely or include a small minority of minor salivary gland histologies. The 
overall rate of CLNI on presentation is variable in published studies and ranges 
from 3.0 to 9.2%.43-47 Longitudinal studies place the lifetime rate of CLNI for oral 
cavity SCC from 9.4 to 17.3%.46, 48, 49 
To consider some of the issues pertinent to determining which tumors 
metastasize to the contralateral neck, it is useful to study the example of the oral 
tongue cancer. Lymphatic metastasis from the tongue can follow different 
patterns depending on the location of the primary tumor. It has been suggested 
by Feind and others that more anterior tumors are at a higher risk for CLNI.45 
They reported CLNI in 4 of 21 (19.0%) of tumors of the anterior 1/3 of the tongue 
and in 3 of 80 (3.8%) of tumors of the middle 1/3 of the tongue. However, in the 
former group, extension to the floor of mouth was noted in all patients with CLNI.  
Tumors that involve the midline are known to be associated with higher 
rates of CLNI. Increasing risk with further graded extension to and across the 
midline was first reported in 1951 by Martin and others50 and more recently by 
Kowalski and others.46, 50 Several papers have been published that attempt to 
define other clinicopathological predictors of CLNI.45-48, 51, 52 However, a rational 
basis for why factors such as T stage, histopatholigical grade and depth of 
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invasion should cause lateralized tumors to metastasize to the contralateral neck 
has generally been lacking. The crux of the rationale for CLNI is most likely 
anatomical. Lymphatic capillaries and collecting trunks that cross the midline 
exist and are utilized more frequently the more centrally located the primary 
lesion.45 Vascular emobilization and perineural infiltration are two other factors 
that provide an anatomically rational explanation for increased CLNI and they 
were shown to correlate with CLNI by Kowalski and others.46 Gonzalez-Garcia 
and others found that peritumoral inflammation correlated with CLNR.52 A 
depressed immune response in this case may allow for more widespread 
dissemination of metastases, including across the midline to the contralateral 
neck.  
Both early and relapse/failure CLNI are known to confer a poor prognosis 
in oral cavity SCC. Gonzalez-Garcia and others reviewed 203 patients with SCC 
of the lateral aspect of the tongue longitudinally and found cervical lymph node 
relapse in 29 patients.52 Of those with relapse in the ipsilateral neck, 14 of 20 
(70%) eventually died of the disease. Of those with relapse in the contralateral 
neck 8 of 9 (89%) eventually died of the disease.  
In the same study, relapse in the contralateral neck occurred only when 
there was no contralateral neck dissection such as in 6 of 80 patients with (T2, 
T3, T4) N0 tumors or tumors with cervical nodes less than 3 cm without 
extracapsular extension. There were no cases of CLNR in 49 N0 or N1 patients 
with lateral tumors that invaded midline of the tongue and who underwent 
modified type III radical neck dissection. However, when considering all patients, 
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the association between contralateral neck dissection and decreased CLNR was 
not statistically significant. These data suggest that bilateral neck dissection was 
at least effective in this small group of patients with tumors invading the midline.  
In a study of stage I and II oral cavity SCC, Lim and others found only one 
case of occult CLNI in 25 elective contralateral neck dissections in a total patient 
sample of 54.53 Patients were followed for a mean of 56.3 months and no cases 
of CLNR were found. All patients had unilateral lesions that did not extend across 
the midline.  
The type of elective contralateral neck dissection warranted may or may 
not include Level IV. Woolgar and others showed that large mobile SCCs that 
extend across the midline often exhibit an erratic pattern of CLNI and they 
recommend neck dissection down to level IV bilaterally in these patients.47 
Kowalski and others found that in 41 patients submitted to contralateral modified 
radical neck dissection for oral cavity SCC, only once were nodes found in Level 
IV.46 Twenty-four patients who did not receive elective contralateral neck 
dissection had positive lymphatic involvement in Levels I-III, as did 19 of 79 who 
submitted to a contralateral supraomohyoid neck dissection. Northrup and others 
noted that CLNR occurred almost exclusively in the subdigastric area.49 Prins-
Braam and others suggested that when contralateral nodes are found, they are 
usually found at an anatomically higher level than positive ipsilateral nodes.54   
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Adenoid Cystic Carcinoma: A Special Case 
 While most minor salivary gland tumors metastasize through the 
lymphatics via then neck, one class, adenoid cystic carcinoma, is known to 
commonly metastasize through perineural invasion as well.  
 ACC has been found more commonly in the minor salivary glands than in 
the major salivary glands by some authors.27, 55 In a yet to be published report, 
we found slightly more single-primary cases of ACC treated by definitive surgical 
resection in the major salivary glands (1117) than in the minor salivary glands 
(995) in population-based data. Of the major salivary glands, the parotid gland 
and submandibular glands harbored the biggest share of cancers (567 and 471 
respectively) and the oral cavity with its various sub-sites was most frequently 
involved among minor salivary gland sites (618).  
Buchholz and colleagues have had success treating adenoid cystic 
carcinomas with fast neutron radiotherapy.56 They reported 5-year actuarial local 
control and locoregional control rates of 76% and 63%, respectively. Eighty-one 
percent (17/21) of patients treated with neutron therapy alone and 100% (13/13) 
of the patients treated with neutron therapy and surgery achieved local control. 
 
Conclusions 
 We present a population based survey of minor salivary gland malignancy 
and an analysis of the predictors of lymph node metastasis. African Americans 
with minor salivary gland cancer may present with more advanced disease. 
Grade is a significant predictor of metastasis for adenocarcinoma and 
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mucoepidermoid carcinoma but not for adenoid cystic carcinoma and other 
subtypes. Tumor size is often considered in the decision to perform neck 
dissection, yet it was not a significant predictor of nodal metastasis on 
multivariate analysis. We present a prognostic index of lymph node involvement 
for minor salivary gland cancer that uses the presence or absence of four 
factors—male gender, pharyngeal primary site, T3 or T4 stage, and high-grade 
adenocarcinoma or mucoepidermoid carcinoma. This index effectively 
differentiates patients into risk groups for nodal metastasis.  
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Table and Figure Legends 
Table 1: Percentages in parentheses represent the percentage of cancers in the 
site that are the histological type in question. Percentages in the bottom row 
represent the percentage of the total found in that site.  
 
Table 2: *Pearson Chi square test double-sided p-value. SE: Standard Error. 
The T stage is unknown for 92 patients who had distant metastasis because 
distant metastasis overrides tumor extension data in SEER coding. LN = Lymph 
Node.  
 
Table 3: 1533 patients are included in this analysis. The p-value is listed for the 
odds ratio of each variable and for the Wald statistic for inclusion of complete 
categorical variable groups. Cases with distant metastasis are excluded from this 
analysis because T stage was not recorded/unknown when there was distant 
metastasis. The Hosmer-Lemeshow test for this regression had a p-value of 
0.023. The NagelKerke R Square is 0.526. ***p < 0.001. **0.001 < p <= 0.010. 
*0.010 < p <= 0.050. †The number of lymph node positive cases is too small for 
analysis.  
 
Table 4: Odds ratios compare groups to the group with no factors present. ADC: 
Adenocarcinoma. MEC: Mucoepidermoid carcinoma. N = 1805 
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Table 5: N is the number of cases that fall in the group. The logistic regression 
includes the covariate controls listed in Table 3. Hosmer-Lemeshow statistic p-
value is 0.133 indicating no difference between predicted and observed values. 
NagelKerke R square is 0.464. 
 
Figure 1: The blue curve represents patients who were lymph node negative on 
presentation and the green curve represents patients with lymph node 
involvement on presentation.  
 
